Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
Adult
Aged
Aged, 80 and over
Apoptosis
Brain Neoplasms
/ genetics
Cell Cycle
Cell Movement
Cell Proliferation
Chemoradiotherapy
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
MAP Kinase Signaling System
/ drug effects
Male
Melanoma
/ genetics
Middle Aged
Mutation
Prognosis
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins B-raf
/ antagonists & inhibitors
Radiation Tolerance
Radiotherapy
Retrospective Studies
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
Cross-resistance
JARID1B/KDM5B
Melanoma
Radiotherapy
Repopulation
Resistance
Slow-cycling cells
Targeted therapy
Therapy sequencing
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
21
11
2018
revised:
22
12
2018
accepted:
29
12
2018
pubmed:
6
2
2019
medline:
22
5
2020
entrez:
6
2
2019
Statut:
ppublish
Résumé
Treatment of patients with metastatic melanoma is hampered by drug-resistance and often requires combination with radiotherapy as last-resort option. However, also after radiotherapy, clinical relapses are common. Our preclinical models indicated a higher rate of tumour relapse when melanoma cells were first treated with BRAF The level of cross-resistance between combined MAPK inhibition and radiotherapy is dependent on the treatment sequence. JARID1B may represent a novel therapy-overarching resistance marker.
Identifiants
pubmed: 30721788
pii: S0959-8049(19)30001-2
doi: 10.1016/j.ejca.2018.12.024
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
137-153Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.